SGLT2 Inhibitors Improve Outcomes in Frail Adults with Type 2 Diabetes but Are Underused

Two analyses presented at Kidney Week 2026 link SGLT2 inhibitors to improved kidney, cardiovascular, and survival outcomes in patients with type 2 diabetes. Despite these benefits, more than half of patients with diabetic chronic kidney disease are not receiving these treatments. This highlights a gap in the adoption of effective therapies for this vulnerable population.

Originally published by gnews